beta-2'-deoxythioguanosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

beta-2'-deoxythioguanosine: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	3000603
CHEMBL ID	3250476
SCHEMBL ID	531274
SCHEMBL ID	9634767
MeSH ID	M0055942

Synonyms (58)

Synonym
beta-thioguanine deoxyriboside
2-amino-9-(2-deoxy-beta-d-erythro-pentofuranosyl)-1,9-dihydro-6h-purine-6-thione
nsc-71261
guanosine, 2'-deoxy-6-thio-
2'-desoxy-6-thioguanosine
thio
6-mercaptoguaninedeoxyriboside
thioguanine deoxyriboside
thiodeoxyguanosine
2'-deoxythioguanosine
789-61-7
nsc71261
2-amino-9-(2-deoxy-.beta.-d-erythropentofuranosyl)-9h-purine-6(1h)-thione
2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1h-purine-6-thione
hsdb 7074
tgdr
nci-c01581
brn 1224220
beta-2'-deoxy-6-thioguanosine monohydrate
beta-2'-deoxythiol guanosine
beta-tgdr
thioguanine 9betad-2'-deoxyriboside
beta-2'-deoxythioguanosine
b-tgdr
2'deoxy-6-thioguanosine
ccris 195
thioguanine deoxyriboside (van)
9h-purine-6(1h)-thione, 2-amino-9-(2-deoxy-beta-d-erythro-pentofuranosyl)-
beta-thioguanidine deoxyriboside
2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione
6-thio-2'-deoxyguanosine
kr0rfb46df ,
unii-kr0rfb46df
S7757
2'-deoxy-6-thio guanosine
CHEMBL3250476
2'-deoxy-6-thioguanosine
SCHEMBL531274
6-thio-dg
SCHEMBL9634767
AC-32335
DTXSID4021345
beta-thioguanosine deoxyriboside
2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-1h-purine-6-thione
2-amino-9-(2-deoxy-.beta.-d-erythro-pentofuranosyl)-6-mercaptopurine
30241-92-0
HY-18762
CS-0014289
2-amino-9-((2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1h-purine-6(9h)-thione
6-thio-dg;\|a-tgdr
6-thio-2 inverted exclamation marka-deoxyguanosine
mfcd00672275
CCG-267279
MS-24022
6-thio-dg;-tgdr
??tgdr
F88129
2'-ddeoxy-6-thio-guanosine

Research Excerpts

Pharmacokinetics

Excerpt	Reference	Relevance
"4 mg/kg, 200 mg/m2, 200 microCi total) was administered to five patients; the radiolabel in the plasma declined with an initial half-life (t1/2) of 14 min and a terminal t1/2 of 19."	( Pharmacokinetics and metabolism of beta-2'-deoxythioguanosine and 6-thioguanine in man. Benvenuto, JA; Bodey, GP; Gottlieb, JA; Loo, TL; Lu, K; Rosenblum, MG, 1982)	0.54

Compound-Compound Interactions

Excerpt	Reference	Relevance
"In a randomized multi-institutional trial of the Eastern Cooperative Oncology Group, 316 patients with advanced measurable colorectal adenocarcinoma were treated with a weekly schedule of 5-fluorouracil given orally and intravenously with oral-5-fluorouracil in combination with cyclophosphamide or 6-thioguanine, or with oral Methyl CCNU administered once every eight weeks."	( Chemotherapy of advanced measurable colon and rectal carcinoma with oral 5-fluorouracil, alone or in combination with cyclophosphamide or 6-thioguanine, with intravenous 5-fluorouracil or beta-2'-deoxythioguanosine or with oral 3(4-methyl-cyclohexyl)-1(2- Carbone, P; Conroy, JF; Douglass, HO; Lavin, PT; Woll, J, 1978)	0.45
"Beta-thioguanine deoxyriboside (betaTGdR) is a purine nucleoside derivative which was studied alone or in combination with arabinosyl cytosine (Ara-C) in patients with solid tumors and acute leukemia."	( Clinical studies of beta-thioguanine deoxyriboside alone and in combination with arabinosyl cytosine. Bodey, GP; Freireich, EM; McCredie, KB; Whitecar, JP, 1976)	0.26

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay ID	Title	Year	Journal	Article
AID1133842	Inhibition of RNA synthesis in mouse L1210 cells assessed as inhibition of tritiated uridine incorporation into nucleic acids	1977	Journal of medicinal chemistry, Mar, Volume: 20, Issue:3	Potential antitumor agents. Some sulfur-substituted derivatives of alpha- and beta-2'-deoxythioguanosine.
AID1133835	Antitumor activity in mouse L1210 cells allografted in mouse assessed as increase in survival time at optimal dose administered qd on days 1 to 5 of challenge relative to control	1977	Journal of medicinal chemistry, Mar, Volume: 20, Issue:3	Potential antitumor agents. Some sulfur-substituted derivatives of alpha- and beta-2'-deoxythioguanosine.
AID1133841	Inhibition of DNA synthesis in mouse L1210 cells assessed as inhibition of tritiated thymidine incorporation into nucleic acids	1977	Journal of medicinal chemistry, Mar, Volume: 20, Issue:3	Potential antitumor agents. Some sulfur-substituted derivatives of alpha- and beta-2'-deoxythioguanosine.
AID1133836	Antitumor activity in mouse L1210 cells allografted in mouse assessed as increase in survival time at optimal dose administered qd on days 1 to 9 of challenge relative to control	1977	Journal of medicinal chemistry, Mar, Volume: 20, Issue:3	Potential antitumor agents. Some sulfur-substituted derivatives of alpha- and beta-2'-deoxythioguanosine.
AID1133840	Antitumor activity in mouse P388 cells allografted in mouse assessed as increase in survival time at optimal dose administered qd on days 1 to 9 of challenge relative to control	1977	Journal of medicinal chemistry, Mar, Volume: 20, Issue:3	Potential antitumor agents. Some sulfur-substituted derivatives of alpha- and beta-2'-deoxythioguanosine.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	17 (68.00)	18.7374
1990's	3 (12.00)	18.2507
2000's	1 (4.00)	29.6817
2010's	4 (16.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	11.49 (24.57)
Research Supply Index	3.43 (2.92)
Research Growth Index	4.92 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (11.49)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	5 (20.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	20 (80.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
cytosine [no description available]	2.1	1	0	aminopyrimidine; pyrimidine nucleobase; pyrimidone	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
nickel Nickel: A trace element with the atomic symbol Ni, atomic number 28, and atomic weight 58.69. It is a cofactor of the enzyme UREASE.. nickel ion : A nickel atom having a net electric charge.. nickel atom : Chemical element (nickel group element atom) with atomic number 28.	2.1	1	0	metal allergen; nickel group element atom	epitope; micronutrient
uric acid Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.. uric acid : An oxopurine that is the final oxidation product of purine metabolism.. 6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.. 7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.	1.96	1	0	uric acid	Escherichia coli metabolite; human metabolite; mouse metabolite
altretamine Altretamine: A hexamethyl-2,4,6-triamine derivative of 1,3,5-triazine.	1.96	1	0	triamino-1,3,5-triazine
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	8.34	1	1	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
lomustine [no description available]	1.96	1	0	N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent
semustine Semustine: 4-Methyl derivative of LOMUSTINE; (CCNU). An antineoplastic agent which functions as an alkylating agent.. semustine : An organochlorine compound that is urea in which the two hydrogens on one of the amino groups are replaced by nitroso and 2-chloroethyl groups and one hydrogen from the other amino group is replaced by a 4-methylcyclohexyl group.	4.3	2	2	N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent; carcinogenic agent
cytarabine [no description available]	3.75	2	1	beta-D-arabinoside; monosaccharide derivative; pyrimidine nucleoside	antimetabolite; antineoplastic agent; antiviral agent; immunosuppressive agent
3-mercaptopropionic acid 3-Mercaptopropionic Acid: An inhibitor of glutamate decarboxylase. It decreases the GAMMA-AMINOBUTYRIC ACID concentration in the brain, thereby causing convulsions.. 3-mercaptopropanoic acid : A mercaptopropanoic acid that is propanoic acid carrying a sulfanyl group at position 3.	2.07	1	0	mercaptopropanoic acid	algal metabolite
azacitidine Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.. 5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia.	4.82	4	2	N-glycosyl-1,3,5-triazine; nucleoside analogue	antineoplastic agent
podophyllotoxin Podophyllum: A genus of poisonous American herbs, family BERBERIDACEAE. The roots yield PODOPHYLLOTOXIN and other pharmacologically important agents. The plant was formerly used as a cholagogue and cathartic. It is different from the European mandrake, MANDRAGORA.	3.34	1	1	furonaphthodioxole; lignan; organic heterotetracyclic compound	antimitotic; antineoplastic agent; keratolytic drug; microtubule-destabilising agent; plant metabolite; tubulin modulator
nickel chloride nickel chloride: RN given refers to cpd with MF of Ni-Cl2. nickel dichloride : A compound of nickel and chloride in which the ratio of nickel (in the +2 oxidation state) to chloride is 1:2.	2.1	1	0	nickel coordination entity	calcium channel blocker; hapten
daunorubicin Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.	3.35	1	1	aminoglycoside antibiotic; anthracycline; p-quinones; tetracenequinones	antineoplastic agent; bacterial metabolite
razoxane Razoxane: An antimitotic agent with immunosuppressive properties.	6.96	1	0	N-alkylpiperazine
etoposide [no description available]	3.34	1	1	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
xanthosine [no description available]	2.17	1	0	purines D-ribonucleoside; xanthosines	Escherichia coli metabolite; human metabolite; mouse metabolite
decitabine [no description available]	1.96	1	0	2'-deoxyribonucleoside
mercaptopurine Mercaptopurine: An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.. purine-6-thiol : A thiol that is the tautomer of mercaptopurine.. mercaptopurine : A member of the class of purines that is 6,7-dihydro-1H-purine carrying a thione group at position 6. An adenine analogue, it is used in the treatment of acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), Crohn's disease, and ulcerative colitis.	2.13	1	0	aryl thiol; purines; thiocarbonyl compound	anticoronaviral agent; antimetabolite; antineoplastic agent
thioguanine anhydrous Thioguanine: An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.. tioguanine : A 2-aminopurine that is the 6-thiono derivative of 2-amino-1,9-dihydro-6H-purine. Incorporates into DNA and inhibits synthesis. Used in the treatment of leukaemia.	5.28	7	2	2-aminopurines	anticoronaviral agent; antimetabolite; antineoplastic agent
6-thioguanosine 6-thioguanosine: RN given refers to cpd without isomeric designation	2.05	1	0	purine nucleoside
alpha-2'-deoxythioguanosine alpha-2'-deoxythioguanosine: structure	2.39	2	0
phosphoramidite phosphoramidite: structure in first source. phosphoramidite : A compound with the general formula (RO)2PNR2. Phosphoramidites can be regarded as phosphites that have an NR2 instead of an OH group, or as amides of phosphorous acid.	2.05	1	0
dianhydrogalactitol Dianhydrogalactitol: One of the cytotoxic dihalohexitols that alkylates and cross-links DNA via an epoxide group during all phases of the cell cycle, resulting in a disruption of DNA function and cell cycle arrest. It has antineoplastic activity and also causes bone marrow toxicity.	6.96	1	0
oligonucleotides [no description available]	2.42	2	0
deoxyguanosine [no description available]	7.27	24	5	purine 2'-deoxyribonucleoside; purines 2'-deoxy-D-ribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
guanosine ribonucleoside : Any nucleoside where the sugar component is D-ribose.	2.38	2	0	guanosines; purines D-ribonucleoside	fundamental metabolite
inosine [no description available]	3.34	1	1	inosines; purines D-ribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
allopurinol Allopurinol: A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.. allopurinol : A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring.	2.36	2	0	nucleobase analogue; organic heterobicyclic compound	antimetabolite; EC 1.17.3.2 (xanthine oxidase) inhibitor; gout suppressant; radical scavenger

Condition	Relationship Strength	Studies	Trials
Leukemia L 1210 [description not available]	2.65	3	0
Experimental Leukemia [description not available]	1.95	1	0
Leukemia, Lymphocytic [description not available]	4.03	3	1
Leukemia, Lymphoid Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts.	4.03	3	1
Bowel Diseases, Inflammatory [description not available]	2.13	1	0
Inflammatory Bowel Diseases Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS.	2.13	1	0
Adenocarcinoma, Basal Cell [description not available]	4.43	5	1
Experimental Neoplasms [description not available]	1.94	1	0
Animal Mammary Carcinoma [description not available]	2.34	2	0
Experimental Mammary Neoplasms [description not available]	2.34	2	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	4.43	5	1
Acute Myelogenous Leukemia [description not available]	4.59	3	2
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	4.59	3	2
Benign Neoplasms [description not available]	2.36	2	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.36	2	0
Cancer of Colon [description not available]	4.59	3	2
Leukocytopenia [description not available]	2.65	3	0
Thrombopenia [description not available]	2.65	3	0
Colonic Neoplasms Tumors or cancer of the COLON.	4.59	3	2
Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).	2.65	3	0
Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.	2.36	2	0
Thrombocytopenia A subnormal level of BLOOD PLATELETS.	2.65	3	0
Leucocythaemia [description not available]	4.03	3	1
Acute Disease Disease having a short and relatively severe course.	4.03	3	1
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	4.03	3	1
Remission, Spontaneous A spontaneous diminution or abatement of a disease over time, without formal treatment.	2.36	2	0
Metastase [description not available]	3.74	2	1
Cancer of Rectum [description not available]	4.3	2	2
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	3.74	2	1
Rectal Neoplasms Tumors or cancer of the RECTUM.	4.3	2	2
Acute Kidney Failure [description not available]	1.96	1	0
Emesis [description not available]	1.96	1	0
Vomiting The forcible expulsion of the contents of the STOMACH through the MOUTH.	1.96	1	0
Acute Kidney Injury Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions.	1.96	1	0
Cancer of Pancreas [description not available]	1.96	1	0
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	1.96	1	0

chemdatabank.com